Abstract Library

#4283 Long-term efficacy and safety of peptide receptor radionuclide therapy (PRRT) in Japanese patients with unresectable neuroendocrine tumour: Japanese phase I and phase I/II extension study

Introduction: PRRT with 177Lu-DOTATATE has been approved in Japan according to Japanese phase I and Phase I/II clinical trials. Primary end point of these clinical studies was safety and response rate, therefore, long-term efficacy and safety of PRRT for Japanese patients with NET are uncertain.

Conference:

Presenting Author: Ichikawa Y

Authors: Kobayashi N, Ono H, Okubo N, Akahoshi K, Kudo A,

Keywords: Neuroendocrine tumour, Peptide receptor radionuclide therapy, Japanese patients,

#3982 Safety and efficacy of peptide radionuclide therapy (PRRT) with 177Lu-DOTATATE for Japanese patients with neuroendocrine neoplasm (NEN): A single-center retrospective study

Introduction: After the approval of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in Japan (June 2021), its treatment experience is increasing, but limited data are available in Japanese patients with neuroendocrine neoplasm (NEN).

Conference:

Presenting Author:

Authors: Okamoto K, Hijioka S, Goto Y, Honma Y, Hirano H,

Keywords: PRRT, 177Lu-DOTATATE, Japanese cohort,

#3958 Treatment strategy for pancreatic NETs smaller than 2 cm should be based on the diagnosis of malignancy as well – New treatment strategy for small pancreatic NETs

Introduction: There are still many unclear issues regarding the treatment of non-functioning small (≤20 mm) pancreatic neuroendocrine neoplasms (pNENs).

Conference:

Presenting Author: Hijioka S

Authors: Hijioka S, Yamashige D, Esaki M, Honda G, Masui T,

Keywords: small pancreatic neuroendocrine neoplasm, tumor size, grading, treatment strategy, Japanese cohort,

#3700 A prospective, multicenter, single-arm, open-label, phase 3 study of Lanreotide Autogel (LAN) in Chinese patients with unresectable, locally advanced or metastatic grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Introduction: The efficacy of LAN has been demonstrated for the treatment of GEP-NETs and associated symptoms in Caucasian (CLARINET; NCT00353496) and Japanese patients but is yet to be explored in the Chinese population.

Conference:

Presenting Author:

Authors: Lu M, Li E, Cao D, Chen J, Zhang N,

Keywords: neuroendocrine, neuroendocrine tumor, efficacy, safety,

#3683 Distinct clinico-pathological features of neuroendocrine liver metastases originating from the pancreas and rectum

Introduction: The treatment response and prognosis still remain poor in the metastatic neuroendocrine neoplasms.

Conference:

Presenting Author: Takahiro T

Authors: Tsuchikawa T, Aya M, Tanaka K, Nakanishi Y, Asano T,

Keywords: Neuroendocrine liver metastasis, pancreas, rectum, clinical characteristics,